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DPA certification. Legislation enacted in 1 996 (SB 668, 
Polanco; Chapter 1 3, Statutes of 1 996) established a certifi­
cation program within the Board, whereby the Board certi­
fies qualified optometrists who complete additional training 
to use specific classes of therapeutic pharmaceutical agents 
(TPA) for a l imited number of eye conditions. [ 16: 1 CRLR 
69 J However, some optometrists who were initially licensed 
before 1 980 have never applied for DPA or TPA certification. 
Dr. Anthony stated that the position of the Board has been 
to continue licensing non-DPA- or TPA-certified optometrists 
under the assumption that their number would eventually 
dwindle due to attrition. He expressed concern, however, that 
current optometric practice is significantly limited and may 
be inadequate without the use of pharmaceutical agents. De­
spite a suggestion by Board President Steven Grant, OD, that 
Board of Pharmacy 
the Board issue a mandate requiring optometrists to receive 
DPA training or lose their l icenses, the Board agreed to 
further investigate the status of uncertified practitioners. Dr. 
Anthony agreed to draft a letter to uncertified optometrists, 
inquiring as to whether they continue active practice and 
whether the nature of their practice is limited by their non­
certified status. At this writing, Dr. Anthony expects to present 
a draft of this letter to the Board for approval at its May 
meeting. 
FUTURE MEETINGS 
• May 1 6- 1 7, 1 999 in San Jose. 
• August 20-2 1 ,  1 999 in Sacramento. 
• November 1 4- 1 5, 1 999 in San Diego. 
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Pursuant to Business and Professions Code section 4000 et seq., the Board of Pharmacy grants licenses and per­mits to pharmacists, pharmacy interns, pharmacy tech­
nicians, pharmacies, pharmacy corporations, nonresident 
pharmacies, wholesale drug facilities, medical device retail­
ers, veterinary food-animal drug retailers, out-of-state dis­
tributors, clinics, and hypodermic needle and syringe distribu­
tors. It regulates all sales of dangerous drugs, controlled sub­
stances, and poisons. The Board is authorized to adopt regu­
lations, which are codified in Division 17 ,  Title 1 6  of the 
California Code of Regulations (CCR). 
To enforce the Pharmacy Law and its regulations, the 
Board employs full-time inspectors who investigate com­
plaints received by the Board. Investigations may be con­
ducted openly or covertly as the situation demands . The Board 
conducts fact-finding and disciplinary hearings, and is au­
thorized by law to suspend or revoke licenses or permits for a 
variety of reasons, including professional misconduct and any 
misconduct substantially related to the practice of pharmacy. 
The Board of Pharmacy is a consumer protection agency 
located within the Department of Consumer Affairs (DCA). 
The Board, which meets five times per year, consists of eleven 
members, four of whom are nonlicensees. The remaining 
members are pharmacists, five of whom must be active prac­
titioners. All Board members are appointed for four-year 
terms. 
MAJOR PROJECTS 
Pharmacy Practice on the Internet 
Over the last few months, the Board and the public have 
witnessed a surge of pharmacy practice activity on the Internet. 
While the Pharmacy Law requires a pharmacy which offers 
to compound, dispense, or refill a prescription for a resident 
of California to be licensed by the 
Board as a nonresident pharmacy, 
the Board's Licensing Committee 
has requested that the Board sponsor legislation that will re­
quire additional disclosure of information on the application 
form specific to Internet pharmacy practice. 
Currently, Deputy Attorney General William Marcus is 
drafting proposed legislation based on the Licensing 
Committee's discussions. The legislation would require an 
Internet pharmacy to disclose specific information on its ap­
plication for licensure, including its Internet name; its corpo­
rate or business name (if different); the names and addresses 
of its officers, directors, partners, and shareholders; and the 
location of each pharmacy which will be performing com­
pounding, dispensing, or refilling of prescriptions, maintain­
ing or reviewing patient profiles, or providing patient con­
sultation. Additionally, the applicant must provide proof that 
it, and any pharmacy or pharmacist it employs or contracts 
with, is licensed or registered as required by the laws of the 
host state. Finally, an Internet pharmacy must provide spe­
cific descriptive information to consumers on its website. 
CURES Update 
For several years, the Board has been involved in a multi­
agency project to automate the current paper-based "tripli­
cate system" used when a physician or other authorized pre­
scriber prescribes, and a pharmacist dispenses, Schedule II 
controlled substances. [ 16: 1 CRLR 69-70; 15:4 CRLR 116; 
15:2&3 CRLR 89] Under the triplicate system, prescribers 
must prescribe Schedule II narcotics on a state-issued tripli­
cate form. The prescriber retains one copy and gives the re­
maining two copies to the patient. To have the prescription 
filled, the patient takes the remaining two parts of the form to 
a pharmacy. The pharmacy endorses the prescription, retains 
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a duplicate, and checks the form for compliance with Health 
and Safety Code section 1 1206. Section 1 1 164 of the Health 
and Safety Code requires the pharmacy to transmit the origi­
nal of the triplicate form to the Department of Justice's (DOJ) 
Triplicate Prescription Program at the end of the month in 
which the prescription was filled. The purpose of the tripli­
cate system is to monitor closely the prescribing and dispens­
ing of Schedule II controlled substances to control effectively 
the abuse and diversion of these narcotics while allowing 
patient access to appropriate medications. However, prescrib­
ers and dispensers complain that the paper-intensive tripli­
cate system is burdensome in light of modern electronic 
recordkeeping methods. 
AB 3042 (Takasugi) (Chapter 738, Statutes of 1996) 
added section 1 1 165 to the Health and Safety Code, which 
requires the Board of Pharmacy and DOJ to establish the 
Controlled Substance Utilization Review and Evaluation Sys­
tem (CURES) to electronically monitor the prescribing and 
dispensing of Schedule II controlled substances by all practi­
tioners authorized to prescribe or 
DOJ and the Board submitted a progress report on the 
data collection project to the legislature on January 1 .  Ac­
cording to the report, CURES has arrived at a key point in 
time, because the Triplicate Prescription Program adminis­
tered by DOJ's Bureau of Narcotic Enforcement has been 
unable to process the vastly increasing number of Schedule 
II controlled substance prescriptions dispensed in Califor­
nia. By the end of 1998, approximately 105,000 California 
practitioners were eligible to obtain triplicate prescription 
forms and prescribe Schedule II controlled substances. Also 
in 1 99 8 ,  those practit ioners issued over 2 .29 mill ion 
Schedule II prescriptions. In that same year, however, the 
Triplicate Prescription Program was able to process only 
39,945 such prescriptions into its existing outmoded auto­
mated system (down from 256,303 in 1995). During the first 
seven months in which CURES was operational, it was able 
to process a total of 892,985 triplicate prescription forms 
transmitted by pharmacies. 
The progress report states that CURES has had a negli-
gible impact on pharmacists . 
dispense them. AB 3042 requires 
that CURES be implemented as a 
three-year pilot project commenc­
ing on July 1 ,  1997, to be admin­
istered concurrently with the ex­
isting triplicate system, to exam­
ine the comparative efficiencies 
between the two systems. Thus, 
CU RES has arrived at a key point in time, 
because the Triplicate Prescription Program 
administered by DOJ's Bureau of N arcotic 
Enforcement has been unable to process the 
vastly increasi ng number of Sched ule  I I  
controlled substance prescriptions dispensed 
in Cal ifornia. 
Computer technology and stan­
dardization is already an integral 
part of the pharmacy i ndustry, 
making pharmacies comfortable 
with and receptive to the use of 
automation in performing their 
daily tasks. Approximately 95% 
the statute requires DOJ and the Board to engage in a major 
data collection process to determine the relative efficiencies 
of the existing triplicate system and the electronic mainte­
nance of Schedule II narcotics data. The data received from 
the state's 5,000 pharmacies are made available online to DOJ, 
the Board, the Medical Board, the Board of Dental Examin­
ers, and the Osteopathic Medical Board of California. 
To facilitate the collection of the required data, the Board 
adopted section 17 1 5.5, Title 1 6  of the CCR, in  1998. Sec­
tion 17 15 .5 requires a dispensing pharmacy to provide speci­
fied information on the patient, prescriber, and pharmacy for 
each prescription of a Schedule II controlled substance; speci­
fies the format in which the information is to be provided; 
establ ishes the timeframe for submitting information; pro­
vides an alternate method of submission and threshold re­
porting requirements for pharmacies without electronic re­
porting capability; specifies the reporting requirements for 
partially filled or dispensed prescriptions; and sets the com­
pliance date for submission of information . The Board con­
tracted with Atlantic Associates, Inc. in Manchester, New 
Hampshire to collect all the information, and mailed several 
notices (with a CURES handbook) to all California pharma­
cies about the new reporting requirements . The Board warned 
pharmacies that CURES is operating concurrently with the 
existing triplicate prescription program; thus, pharmacies are 
still required to mail original triplicate prescription forms to 
DOJ at the end of each month. 
of the 5,000 pharmacies in Cali­
fornia are computerized. CURES has had no impact on pre­
scribers, as they continue to write Schedule II prescriptions 
as they always have. 
A second objective of CURES is to provide flexible 
data analysis to prevent drug diversion according to the 
specialized information requirements of each governmen­
tal user. Through a private contractor, CURES provides 
the flexibility of using standardized output reports or the 
option of customizing data output according to the needs 
of each agency. 
The progress report also made several recommenda­
tions, including the fol lowing: ( 1 )  eventually, legislation es­
tabl ishing CURES as a permanent operational program 
should be pursued; (2) existing Triplicate Prescription Pro­
gram staff should be reclassified to other positions more 
suitable to the investigative and analytical duties they wil l 
perform for CURES; (3) the program should continue to 
capture only information on Schedule II controlled sub­
stances, but it should begin to evaluate the feasibility of 
collecting Schedules III-V controlled substances prescrip­
tion data as wel l ;  and ( 4) the CURES database should even­
tually be expanded to include information received by the 
Board pursuant to section 1782, Title I 6 of the CCR, re­
garding excessive sales of drugs that are subject to abuse. 
The Board has already submitted proposed legislation which 
will continue to fund CURES and extend it until 2003 (see 
LEGISLATION). 
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Board Proposes Regulations Governing 
Specialized Refill Pharmacies 
Recently, many new pharmacy operations and concepts 
have begun to emerge. One such concept is a refill pharmacy, 
which prepares refill prescriptions for another pharmacy. 
While the Board has licensed such pharmacies in the past, it 
has determined that labeling and documentation requirements 
should be established to assure that patients can readily de­
termine where the prescription was filled . Specifically, phar­
macies that receive an original prescription for filling some­
times use another pharmacy for refills. The Board bel ieves 
that this use of a refill pharmacy may result in confusion to 
patients who receive medications and who do not know which 
pharmacy actually provided the medication or whom to con­
tact. This would be especially critical if the medication is dis­
pensed in error or in a form not readily identifiable to the 
patient. Further, the Board believes that the labeling and 
recordkeeping practices by both pharmacies should be con­
sistent, to assure that patient safety and confidential ity are 
maintained. 
possibility that an applicant for a medical device retailer per­
mit would use his/her personal residence or the residence of 
someone else as a licensed premise. Section 1 748.3 would 
explicitly prohibit a medical device retailer from conducting 
business from a private residence. In addition, section 1 748.3 
would prohibit a medical device retailer from locating a ware­
house, the primary purpose of which is storage of medical 
devices, at a private residence. 
At this writing, the Board does not intend to hold a pub­
lic hearing on its proposed adoption of section 1 748.3. How­
ever, it is accepting written comments until May 3 .  
Furnishing of Drugs and Devices by 
Wholesalers and Manufacturers 
Drug diversion is the illicit distribution, prescribing, 
dispensing, or use of controlled substances that are manu­
factured and intended for leg itimate purposes. One of the 
ways in which the Board guards against drug diversion is 
by rev iewing the records of drug wholesalers and manu­
facturers for compl iance with the Pharmacy Law. The 
records of sale, purchase, and 
On February 26, the B oard 
published notice of its intent to 
adopt section 1 707.4, Title 16 of 
the CCR, to address its concerns 
about the use of refill pharmacies. 
Section 1 748.3 would explicitly p rohibit a 
medical device retai ler  fro m  cond ucting 
business from a private residence. 
disposition of dangerous drugs 
and devices are required to be 
made avail able ,  at all times 
during business hours, for in-
The purpose of the Board's proposal is to ( I )  allow a phar­
macy to util ize the services of another pharmacy to provide 
refills if it has a contract for these services or has common 
ownership; (2) specify the labeling requirements for a prescrip­
tion refilled at a refill pharmacy, including the name of the 
refill pharmacy and which pharmacy the patient should con­
tact if he/she has questions (this information may be either on 
the label or in writing accompanying the medication); (3) 
specify the documentation requirements for the originating 
pharmacy and the refill pharmacy; and (4) allow a pharmacy 
to operate as a refill pharmacy as well as fill new prescriptions. 
At this writing, the Board is scheduled to hold a publ ic 
hearing on its proposal to adopt section 1707.4 on May 19 .  
Medical Device Retailer Location Restrictions 
One way in which the Board protects consumers is by 
reviewing the records of medical device retailers and medi­
cal device retailer warehouses. Business and Professions Code 
section 4 1 32(f) requires medical device retailers to make their 
records of sale, purchase, and disposition of dangerous de­
vices available, at all times during business hours, for inspec­
tion by authorized law enforcement officers. When persons 
conduct a medical device retail business from their home or 
the home of someone else, Pharmacy Board inspectors and 
authorized law enforcement officers have encountered prob­
lems gaining access to records because of residential privacy 
issues. 
On March 1 9, the Board published notice of its intent to 
adopt section 1 748.3, Title 1 6  of the CCR, to eliminate the 
spect ion by author ized law 
enforcement officers. All persons who are involved in drug 
transactions must be l icensees (or their designated agents) 
of the Board or an other governmental agency. When 
unauthorized persons are involved in drug transactions, the 
public health, safety, and welfare are put at risk. 
The potential for drug diversion arises when drugs are 
received from manufacturers or wholesalers by non-licensed 
persons. According to the Board, these non-licensed individu­
als frequently divert the drugs for illegal use or sale. These 
drugs may not be maintained according to manufacturers' 
specifications, which can result in harm to patients. Further, 
payment for these drugs may involve non-licensed parties 
whose interest in the transaction is fraudulent. According to 
the Board, these individuals use Board-licensed owners of 
closed-door pharmacies which they set up to operate "straw 
man" businesses. The drugs purchased at the wholesale dis­
count allowed for this type of pharmacy are then sold on the 
black market. 
On March 19 ,  the Board publ ished notice of its intent to 
adopt section 1 783, Title 1 6  of the CCR, to eliminate any 
confusion on the part of drug wholesalers and manufacturers 
regarding with whom they may make arrangements for the 
purchase and delivery of drugs, and to ensure that these drugs 
are maintained at all times by licensees or their designated 
agents. Section 1 783 would define the term "authorized per­
son" to clarify for law enforcement purposes to whom whole­
salers may furnish drugs and from whom they may accept 
payment for drugs. "Authorized person" means a person to 
whom the Board has issued a permit to purchase dangerous 
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drugs or devices for use within the scope of the permit and 
any person so authorized by the law of another state or 
federal law. Section 1 783 would also include provisions 
authorizing delivery of drugs to an agent of an authorized per­
son under specified circumstances, allowing delivery of drugs 
to a hospital pharmacy receiving area under specified circum­
stances, establishing financial arrangements criteria for whole­
salers and manufacturers to accept payment for drugs, and es­
tablishing recordkeeping requirements for all parties involved. 
At this writing, the Board does not intend to hold a pub­
lic hearing on its proposed adoption of section 1 783. How­
ever, it is accepting written comments until May 3 .  
Board Reduces Licensing Fees 
At its January 20 meeting, the Board adopted section 1749 
and amended section 1749. 1 ,  Title 1 6  of the CCR, to reduce 
most of its licensing fees effective July 1 .  This action will 
enable the Board to reduce its reserve fund to approximately 
one year's expenditures, as required by law. [ 16: 1 CRLR 73] 
The Board, however, withdrew its proposed amend­
ment to section 1793.5, which would have reduced initial 
pharmacy technician registration fees from $50 to $25 . The 
Board based this action on a fee audit report presented at 
the meeting by Market Value Planners, which was commis­
sioned by the Board to analyze the Board's licensing fee 
structure to determine whether fees are appropriate for the 
recovery of the actual cost of conducting its various pro­
grams. The report documented that the $50 fee charged for 
pharmacy technician registration is well below the Board's 
$ 143 cost of processing the application; thus, a reduction 
would be inappropriate. 
The Office of Administrative Law approved the Board's 
amendments on April 20. 
Restocking of Ambulances with Supplies and 
Medications 
At its October 1998 meeting, the Board agreed to con­
vene a multi-agency task force to explore legal issues related 
to the restocking of ambulance supplies (including drugs) by 
hospitals. An advisory opinion from the Health Care Financ­
ing Administration's Office of the Inspector General, which 
concluded that a hospital 's restocking of ambulance supplies 
likely violates federal anti-kickback law and raises antitrust, 
tax, pharmacy, contract, and False Claims Act issues, 
prompted hospitals to discontinue restocking ambulances with 
supplies and drugs. In turn, some ambulances began to pur­
chase, store, and restock medications and supplies; for con­
trolled narcotics, they were using the license and DEA cer­
tificate of their contracted medical director. Because the Board 
does not believe the Pharmacy Law permits this practice, it 
decided to convene the task force with representatives from 
the Department of Health Services (DHS) and the Emergency 
Medical Services Authority (EMSA). [ 16: 1 CRLR 71 J 
At its March meeting, the Board approved a report and 
recommendation of its Licensing Committee that the Board 
sponsor legislation to authorize the restocking of ambulances 
by hospital pharmacies and by other providers if certain 
requirements are met. For example, the purchase of drugs 
and devices would be under the authority of the local emer­
gency medical services director, and the licensed emergency 
medical technician and/or paramedic would be responsible 
for the maintenance and recordkeeping of the dangerous drug 
and device stock. 
At this writing, the Board is still working with DHS and 
EMSA to draft appropriate language for the legislation. 
Implementation of the FDA Modernization 
Act of 1 997 
The FDA Modernization Act of  1997, which became ef­
fective in November 1 998, requires FDA and the fifty states 
to enter into a memorandum of understanding (MOU) regard­
ing the compounding of drugs.  Compounding is the process 
by which a pharmacist combines, mixes, or alters ingredients 
to specialize a medication for a patient, at the direction of a 
physician. Section 503A of the Act recognizes compounding 
as an element of the practice of pharmacy that is to be regu­
lated by the states, and distinguishes it from "manufactur­
ing" which falls within the jurisdiction of the FDA. The pur­
pose of the section is "to ensure continued availability of com­
pounded drug products as a component of individualized 
therapy, while limiting the scope of compounding so as to 
prevent manufacturing under the guise of compounding." The 
purpose of the MOU is to address the interstate distribution 
of "inordinate amounts" of compounded drug products and 
the related issue of state investigations of complaints regard­
ing this distribution. 
The law instructs the FDA and the National Association 
of Boards of Pharmacy (NABP) to develop a standard MOU 
for state boards. The goal of the MOU is to obtain state agree­
ment on two issues: ( 1 )  protocols for the appropriate investi­
gation of complaints relating to compounded drug products 
shipped out-of-state; and (2) establishment of appropriate 
restrictions on the amount of compounded drugs shipped in 
interstate commerce, including "safe harbors" for pharma­
cists who distribute compounded products in interstate com­
merce. Pharmacies located in a state that did not sign an MOU 
by the law's effective date (November 2 1 ,  1998) are subject 
to FD A's "safe harbor" provision, whereby compounded prod­
ucts may not exceed 5% of the total prescription orders dis­
pensed or distributed by that pharmacy. [ 16: 1 CRLR 71-72] 
At its March meeting, the Licensing Committee advised 
the Board that NABP circulated a draft MOU for comment in 
January. Once FDA adopts the final version of the MOU, the 
Board will consider it, along with the Licensing Committee's 
recommendation that the Board sign it. 
LEG ISLATION 
SB 1308 (Committee on Business and Professions), as 
amended April 1 4, would enact various technical changes 
affecting licensing boards within DCA. Several of the bill's 
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provisions would amend the Pharmacy Act in the Business 
and Professions Code, including the following: 
• SB 1 308 would amend section 4008 to require the salary 
of the Board's inspectors who are pharmacists to be within 
5% parity of pharmacists employed by the University of 
California. 
• The bill would amend section 4022 to revise the defini­
tion of "dangerous drug or device" to include drugs or 
devices bearing the statement "Rx only." This change 
would conform California's definition of"dangerous drug 
or device" to the federal definition. 
• SB 1 308 would add section 4040.5 to the Code to define 
"reverse distributor" as a per-
research, and extend the program until July 1 ,  2003 (see 
MAJOR PROJECTS).  The bill would require the Board 
to submi t  to the legis lature annual reports on the 
effectiveness of the CURES program on January 1 ,  2000, 
200 1 ,  and 2002. [S. Appr] 
AB 141 (Knox), as introduced on January 1 1 ,  would 
require the Board to conduct a study of the incidence of 
medication errors in pharmacies in California, employing a 
methodology that uses "test" prescriptions distributed to a 
statistically s ignificant cross-section of pharmacies in the 
state. The bill would define a "test" prescription as one that 
is prepared solely for the purposes of this study and not for 
the actual medical needs of a 
son who acts as an agent for 
pharmacies, drug wholesalers, 
manufacturers, and other enti-
ties by receiving, inventorying, 
AB 1 4 1  (Knox), as introduced on January 1 1 , 
would require the Board to conduct a study 
of the incidence of medication errors i n  
patient, and would require all 
"test" prescription drugs, after 
examination for purposes of the 
study, to be forwarded to the 
Board to remain in its custody pharmacies in California. and managing the disposition 
of outdated or nonsalable con-
trolled substances. The bill would amend section 4043 to 
expand the definition of "wholesaler" to include a "cus­
toms broker" and "reverse distributor," thus requiring cus­
toms brokers and reverse distributors to be licensed as drug 
wholesalers. 
• The bill would amend section 4057 to permit the Board to 
control through regulations (rather than statute) items that 
may be stored outside a pharmacy's licensed premises. 
• SB 1 308 would amend section 4078 to permit a pharma­
cist to place a false label on a prescription if the labeling 
is a necessary part of a clinical or investigational drug 
program approved by the FDA or a legitimate investiga­
tional drug project involving a drug previously approved 
by the FDA. The bill would also permit false labeling in 
situations where, in the medical judgment of the prescriber, 
the labeling is necessary for the proper treatment of the 
patient. 
• The bill would amend section 4204 to allow a pharmacist 
to perform skin .puncture in the performance of routine 
drug therapy-related patient assessment procedures. Ex­
isting law limits a pharmacist's performance of skin punc­
ture to skin puncture for the purposes of training and as­
sisting patients or to monitor medical conditions (includ­
ing diabetes). SB 1 308 would remove these limitations. 
• SB 1 308 would also amend section 4202 to require an 
applicant for registration as a pharmacy technician to be a 
high school graduate or to possess a general education 
development equivalent. 
• Section 4402 would be amended to provide for the can­
cellation of l icenses which are not renewed within 60 days 
by the Board, rather than by operation of law. 
• Finally, SB 1 308 would amend section 1 1 165 of the Health 
and Safety Code to expand the purposes of the CURES 
program to include statistical analysis ,  education, and 
until destroyed. The bill would 
require the Board, in designing the study, to confer with the 
scientific and academic community to ensure that the study 
is based on sound scientific and analytic principles. The 
study is designed to measure the frequency and describe the 
type of medication errors occurring in California, to improve 
patient safety, and to identify broader issues that may be­
come the basis for instituting profession-wide standards and 
changes (see RECENT MEETINGS). AB 1 4 1  would also 
require the Board to issue a report of its findings from the 
study to the legislature by December 1 ,  2002. 
Last year, Governor Wilson vetoed AB 1 889 (Knox), a 
similar bill. In his veto message, the Governor stated that the 
bill 's reference to "placebo" prescriptions was inappropriate, 
and that any such study should use the term "fictitious" rather 
than "placebo" to describe prescriptions. AB 14 1  addresses 
that concern by using the term "test." Governor Wilson also 
suggested that a study of this problem could by done by na­
tional organizations rather than the Board. [ 16: 1 CRLR 75) 
At its March 24 meeting, the Board voted (with pharma­
cist member Darlene Fujimoto abstaining) to support AB 14 1  
i n  concept, but t o  withhold its full support pending appropri­
ate amendments allocating funding for the study and ensur­
ing the confidentiality of those who participate in the study. 
[A. Appr) 
AB 261 (Lempert), as introduced on February 3 ,  would 
permit physicians and pharmacists to enter into protocols 
under which pharmacists could adjust patients' drug therapy. 
Under existing law, pharmacists may adjust patients' drug 
therapy only in specified practice settings and for home health 
care and patients covered by managed care plans. 
Under AB 26 1 ,  protocols for drug therapy would be de­
veloped by health professionals, including physicians, phar­
macists, and registered nurses. At minimum, the protocol 
must require that the medical records of the patient be 
available to both the patient ' s  prescriber and the phar­
macist, and that the procedures to be performed by the 
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pharmacist relate to a condition for which the patient has 
first seen a physician. AB 26 1 would permit a pharmacist 
to order or perform routine drug therapy-related patient 
assessment procedures ( including temperature, pulse, and 
respiration), order drug therapy-related laboratory tests, 
administer drugs and biological s  by injection pursuant to a 
prescriber's order, and adjust the drug regimen of a patient 
pursuant to a specific written order or authorization made 
by the patient's prescriber for the individual patient and in 
accordance with the protocol. AB 26 1 also would allow a 
patient's prescriber to prohibit, by written instruction, any 
adjustment or change in the patient's drug regimen by the 
pharmacist. Finally, the bill would require the pharmacist 
to provide to the supervising physician in writing any change, 
adjustment, or modification of an approved preexisting treat­
ment or drug therapy within 24 hours. 
AB 26 1 is sponsored by the California Pharmacists As­
sociation (CPhA) and is opposed by the California Medical 
Association. At its March 24 meetiri'g, the Board voted unani­
mously to support AB 26 1 .  [A. Health} 
AB 1496 (Olberg), as amended on April 14, would add 
section 4052.5 to the B usiness and Professions Code to 
establish a new "home medical equipment services provider" 
(HMESP) l icensure category under the Board to replace the 
"medical device retailer" category, and expand the definition 
of those who must be l icensed as home medical equipment 
services prov iders. S pec ifi cal l y, AB 1 496 would 
replace references to "medical device retailer" with the term 
"HMESP" to create a new category of licensure, and define 
an HMESP as an individual, entity, or corporation engaged 
in the business of providing home medical equipment ser­
vices to unrelated sick or disabled individuals where those 
individuals reside. AB 1 496 would define "home medical 
equipment" as technologically sophisticated medical devices 
usable in a home care setting, including but not limited to 
oxygen and oxygen delivery systems, ventilators, continuous 
positive airway pressure devices, respiratory disease manage­
ment services, hospital beds and commodes, electronic and 
computer-driven wheelchairs and seating systems, apnea 
monitors, dangerous devices, distribution of medical gases 
to end users for human consumption, and any other similar 
equipment as defined by regulations adopted by the Board. 
AB 1 496 would require HMESP licensees to have emer­
gency services available 24 hours per day, 365 days per year, 
for equipment maintenance if equipment malfunction would 
threaten a patient's health. The bill would exempt HMESP lic­
ensees that dispense or provide hospital beds or wheelchairs 
pursuant to a prescription from paying licensing fees as bed­
ding or furniture dealers. Additionally, the bill would exempt 
from HMESP licensure specified entities and practitioners who 
already have various licenses, unless the entities or practitio­
ners furnish home medical equipment services through a sepa­
rate entity. These exemptions include certain home health agen­
cies, hospitals, pharmacies, hospice programs, nursing homes, 
veterinarians, dentists, and emergency medical services. 
The bill's sponsor, the Cal ifornia Association of Medi­
cal Products Suppliers (CAMPS) ,  asserts that consolidating 
home medical equipment providers' licensure requirements 
"under one roof' will increase efficiency and reduce costs. 
CAMPS further argues that a consolidated form of licensure 
will improve public safety as there has been significant growth 
in home health care and increased sophistication in the types 
of care, equipment, and supplies used in the home. Accord­
ing to CAMPS, current law provides inadequate protection 
of consumers because it fails to specify what type of equip­
ment or supplies must be regulated but merely refers to the 
presence of a warning label. Specifically, existing law de­
fines "dangerous device" as any device unsafe for self-use, 
including any device that bears the statement "Caution: Fed­
eral law restricts this device to sale by or on the order of a 
[blank] ," with the blank to be filled in with the designation of 
the practitioner licensed to use or order use of the device. 
Finally, CAMPS argues that the expanded l icensure scope 
will curb Medicare and Medi-Cal fraud in the provision of 
home medical equipment services. 
At its March 24 meeting, the B oard took an "oppose un­
less amended" position on AB 1 496. According to the Board, 
in the eight years it has licensed medical device retailers, it 
has not received complaints from patients regarding the 
services and equipment provided by medical device retailers. 
Instead, its sole enforcement activity has been to investigate 
complaints of unlicensed activity filed by licensed medical 
device retailers. The Board contends that if the intent behind 
AB 1496 is to combat fraud against the Medi-Cal program, 
the bill should be amended to move the licensing and regula­
tion of the "home medical equipment services providers" listed 
in the bill to OHS, which is responsible for the Medi-Cal 
program. [A. Appr} 
AB 660 (Cardenas). Existing law generally prohib­
its a person from dispensing a prescription unless he/she 
is a pharmacist, in which case a prescription must be given 
to the pharmacist. However, a pharmacist may refill a 
prescription without the prescriber ' s  authorization if the 
prescriber i s  unavai lable to authorize the refi ll and if, in  
the pharmacist's professional judgment, failure to refi l l  
the prescription may in terrupt the patient ' s  ongoing care 
and have a significant adverse effect on the patient 's  well­
being. 
As amended April 28, AB 660 would specify that, dur­
ing the period commencing November 1 ,  1 999 and ending 
February 29, 2000, ( 1 )  a prescriber is deemed unavailable 
to authorize a refill if confronted with problems caused by 
computer fai lures arising from the inability of computers to 
properly handle dates; and (2) a pharmacist may refill a pre­
scription, based upon a request made by the patient who is 
taking the medication, for up to and including 90 days from 
the date of the request. The purpose of the bill is to ensure 
that possible delays in the refills of patient prescriptions will 
not further complicate potential impacts on public safety 
caused by the Y2K problem. [A. Floor] 
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AB 724 (Dutra), as amended April 27, would provide 
that, notwithstanding any other provision of law, during the 
period commencing December 1 ,  1999, and ending Febru­
ary l ,  2000, a pharmacist shall refill any refillable prescrip­
tion with medication sufficient for a period up to and 
including 60 days, subject to the number and terms of 
authorized refills, upon request of the person on whose 
behalf the prescription was written. The bill would autho­
rize a pharmacist, during that same period, to refill any 
refillable prescription with medication sufficient for a pe­
riod up to and including 60 days, subject to the number and 
terms of authorized refills, if the pharmacist determines that 
it is necessary to fill the prescription for the extended 
period to prevent possible harm to the person on whose be­
half the prescription was written that might result from a 
Y2K problem complication or failure, or the potential for 
those events. [A. Appr] 
SB 404 (Alpert), as amended March 1 8, would autho­
rize a pharmacist to initiate emergency contraception drug 
therapy in accordance with written guidelines or protocols 
previously established and approved for his/her practice by a 
practitioner authorized to prescribe drugs. [S. B&P J 
AB 1430 (Bates), as amended April 23 ,  would make a 
number of changes relating to the prescription and receipt of 
drugs by Board licensees. Under existing law, dangerous drugs 
or devices ordered by an entity licensed by the Board must be 
delivered to the licensed premises and signed for and received 
by the pharmacist-in-charge or other designated person. A 
dangerous drug or device transferred, sold, or delivered to 
any person in the state may only be transferred, sold, or de­
livered to an entity licensed by the Board, to a manufacturer, 
or to an ultimate user or the ultimate user's agent. AB 1430 
would provide that, when dangerous drugs or dangerous 
devices are ordered for an entity licensed by the Board and 
delivered to the licensed premises, those drugs or devices must 
be signed for and received by a pharmacist licensed by the 
Board. The bill would make a similar, related change with 
respect to the delivery of dangerous drugs or devices to a 
hospital pharmacy. The bill would also permit a dangerous 
drug or device to be transferred, sold, or delivered to any 
entity authorized by law to possess or handle dangerous 
devices. 
Existing law requires that oral and electronic data trans­
mission of prescriptions be reduced to writing. AB 1430 
would eliminate that requirement, so long as a hard copy 
can be produced upon request. The bill would also autho­
rize prescribers and pharmacists to enter prescriptions and 
orders directly into a pharmacy's or hospital 's computer from 
any location, with permission of the pharmacy or hospital. 
The bill would similarly permit a prescriber to authorize 
his/her agent to enter a prescription on his/her behalf 
directly into a furnisher's computer, with permission of the 
furnisher. 
Existing law requires, within 24 hours after any purchaser 
in this state gives any order for a Schedule II controlled 
substance to an out-of-state wholesaler or manufacturer for 
delivery in this state, that the purchaser forward to the Attor­
ney General, by registered mail, a copy of the order. AB 1430 
would end that requirement. 
This bill is sponsored by Kaiser Permanente and is 
supported by CPhA. According to Kaiser, this bill would 
expedite access to prescription medications while decreas­
ing errors and lowering the cost of medical care by allow­
ing physicians and their authorized agents and pharmacists 
to transmit prescriptions and hospital medication orders 
directly to a hospital or pharmacy computer from wherever 
they are. According to Kaiser, it will also allow electronic 
storage of such orders and prescriptions instead of error­
prone and costly paper storage. Kaiser also states that the 
bill will enable physicians, and other groups of practitio­
ners, to order, receive, and use prescription medication 
supplies as a group, instead of requiring each individual to 
pay for and use his/her own supply. Kaiser further argues 
that this bill will keep pharmacists from being interrupted 
from patient-care duties just to sign a delivery sheet when 
another person licensed by the B oard could sign for the 
delivery. Finally, Kaiser states that this bill would repeal an 
unused and unnecessary requ i rement for report ing 
out-of-state controlled substance purchase and shipment 
transactions to the Attorney General. According to Kaiser, 
this provision was never enforced, and if it were enforced it 
would provide no benefit and add substantial cost to the 
health care system. [A. Appr] 
SB 838 (Figueroa), as amended April 28,  would allow 
the Board to register a nonresident pharmacy that is orga­
nized as a limited liability company (LLC) in the state in which 
it is licensed. 
Merck-Medco Managed Care is sponsoring this bill to 
clarify that the Board may continue its long-standing prac­
tice of registering nonresident pharmacies that are organized 
as LLCs in their home states. An LLC-a hybrid between a 
partnership and a corporation-is a relatively new form of 
business organization in California. The Board registered out­
of-state LLC pharmacies at least through 1 997. At that time, 
DCA analyzed some uncodified language in the LLC law 
which prohibits the organization of an LLC for the rendering 
of professional services. Based on DCA advice, the Board 
began to reject licensure applications from out-of-state LLC 
pharmacies. [ I 6: 1 CRLR 70-7 I] The sponsor and its sup­
porters maintain that this bill will clarify ambiguity created 
by issuance of various legal opinions on the topic, and that 
certainty in the law is necessary in order to continue to pro­
vide low-cost mail order medications. [S. B&PJ 
SB 188 (Leslie). Existing law generally prohibits any 
person from selling or dispensing any dangerous drug, or 
dispensing any prescription, unless he/she is a licensed phar­
macist. However, a licensed hospital that contains 1 00 beds 
or fewer and does not employ a full-time pharmacist may 
purchase drugs at wholesale for administration, under 
the direction of a physician, to patients registered in the 
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hospital or to emergency cases under treatment in the hos­
pital. These hospital drug dispensing activities operate un­
der a so-called "limited drug room license." As amended 
April 6, SB 1 88 would authorize hospitals that have a lim­
ited drug room license and that meet the statutory defini­
tion of a "small and rural hospital" to dispense drugs to out­
patients under limited circumstances. The bill would limit 
those circumstances to cases where a physician determines 
that a particular drug regimen must be immediately initi ­
ated or continued; the physician reasonably believes that a 
retail pharmacy outside the hospital is not available within 
a 30 mile radius or within 30 minutes of travel as measured 
by the mode of travel the patient will employ; the quantity 
of drugs dispensed is limited to the amount needed to as­
sure necessary and uninterrupted therapy while the drugs 
are not readily available; and the physician dispensing the 
drugs has complied with the disclosure and labeling require­
ments applicable to dispensing at a pharmacy. The bill would 
also require hospitals that utilize this new procedure for 
dispensing drugs to outpatients to have a pharmacist con­
sultant to monitor and review the dispensing operation. The 
bill is designed to assure patients in rural areas that their 
needs for medication can be met in a reasonable manner. 
[A. Health] 
RECENT MEETINGS 
At the Board's January meeting, the Licensing Commit­
tee recommended that the Board initiate the rulemaking pro­
cess to amend section 17 14, Title 1 6  of the CCR, to authorize 
pharmacies to establish a "drive-through" portion separate from 
the licensed pharmacy premise so long as ( 1 )  the pneumatic 
tube used to transport the prescriptions and medication from 
the pharmacy to the consumer is secure, and (2) the drive­
through includes a confidential two-way video and audio com­
munication capability to enable the pharmacist to engage in 
oral consultation. However, Deputy Attorney General Bill 
Marcus advised the Board that the proposal does not conflict 
with current law and does not require regulatory changes. Thus, 
the Board adopted the following policy statement: "The Board 
recognizes that an increasing number of pharmacies employ 
or intend to employ drive-through pharmacies for physical 
delivery of prescribed drugs to patients. Any pharmacy doing 
so should remember that it must comply with all the laws and 
regulations governing pharmacy, including: ensuring compli­
ance with laws and regulations governing patient profiles, 
patient consultation, privacy and confidentiality, and the secu­
rity and dispensing or refilling of prescription drugs." 
At the Board's March meeting, Richard Abood, R.Ph. ,  
J.D., Professor of Pharmacy Practice at the University of the 
Pacific School of Pharmacy, gave a presentation to the Board 
on the important issue of prescription errors. Dr. Abood re­
ported the results of a recent pharmacist error survey in which 
53% of the pharmacists surveyed admitted to committing a 
drug error within the prior 60 days. According to the survey, 
wrong drugs and wrong dosages accounted for over 80% of 
the pharmacists' errors. Over 85% of chain pharmacists and 
66% of independent pharmacists cited workload issues, and 
53% of the respondents cited look-alike or sound-alike drug 
names, as the reason for their errors. 
Dr. Abood's presentation focused on the legal ramifi­
cations of prescription errors. He noted that the current trend 
has been for courts to hold pharmacists to an increasingly 
higher standard of care regarding  pharmacist judgment, and 
to hold corporations liable under a theory of corporate neg­
ligence for the acts of pharmacists employed by them. Dr. 
Abood spoke briefly about ways to manage the risk of 
liability to pharmacists and harm to patients. He noted that 
pharmaci sts are often discouraged from reporting their 
errors immediately by the overzealous disciplinary actions 
taken by state boards of pharmacy and employers. He 
stressed the need for developing quality assurance plans that 
provide incentives to pharmacists to report their errors and 
address the problems of workload which lead to prescrip­
tion errors. 
As noted above, a majority of the Board voted to support 
AB 141  (Knox), which would require the Board to conduct a 
study of the incidence of medication errors in pharmacies in 
California. The Board hopes to identify what types of medi­
cation errors are occurring and to develop regulatory stan­
dards and changes targeted at such errors to improve patient 
safety. Further, the Board devoted the April 1 999 issue of its 
Script licensee newsletter to the issue of medication error re­
porting. Finally, the Legislation and Regulation Committee 
is currently developing, at the direction of the Board, regula­
tory changes which would require pharmacies to implement 
a quality assurance program to address and prevent the recur­
rence of prescription errors. 
FUTURE MEETINGS 
• May 1 9-20, 1 999 i n  San Diego. 
• July 28-29, 1 999 in San Francisco. 
• October 20-2 1 ,  1 999 in Sacramento. 
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